CoChat
Sign Up
Cited by 100Treatment of Major DepressionSchizophrenia research and treatmentAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

McIntyre, Roger S., Florea, Ioana, Tonnoir, Brigitte, Loft, Henrik, Lam, Raymond W., Christensen, Michael Cronquist·2017·The Journal of Clinical Psychiatry
DOI 10.4088/jcp.16m10744
Open this paper in CoChat — free account

Abstract

OBJECTIVE: This post hoc analysis investigates the effect of vortioxetine on cognitive functioning and depressive symptoms in working adults with major depressive disorder (MDD). METHODS: Population data from FOCUS, a double-blind, randomized, placebo-controlled study investigating the efficacy of vortioxetine versus placebo on cognitive functioning and depression in patients with MDD, were used to analyze mean change from baseline scores for the Digit Symbol Substitution Test (DSST), Trail Making Test A/B (TMT-A/B), Stroop, and Perceived Deficits Questionnaire (PDQ). FOCUS, conducted from December 2011 through May 2013, included adult patients with recurrent MDD according to DSM-IV-TR criteria. Change in depression severity (Montgomery-Asberg Depression Rating Scale [MADRS] total score) was analyzed using data from 3 additional short-term placebo-controlled studies (2 of which included duloxetine) and 1 relapse prevention study. Analyses were done according to patients' working status at baseline and workplace position. All analyses were made versus placebo. RESULTS: In FOCUS, the effect versus placebo on the DSST was 5.6 for 10 mg and 5.0 for 20 mg (P < .001 for both doses) in working patients; the effect was 4.0 (P < .001 for both doses) in total study population. The effect remained significant when adjusting for change in MADRS. In patients with "professional" positions, the effect was 9.2 for 10 mg (P = .006) and 9.0 for 20 mg (P = .001). A similar pattern of results was also observed for TMT-A/B, Stroop, PDQ, and MADRS total score. The efficacy of duloxetine was not different in working patients (MADRS). CONCLUSIONS: The beneficial effects of vortioxetine on objective and subjective measures of cognitive functioning are greater in working patients with MDD; the observed benefits were independent of improvement in depressive symptoms. TRIAL REGISTRATION: This study is a secondary analysis of data from 5 registered trials: ClinicalTrials.gov identifiers: NCT01422213, NCT00635219, NCT00735709, NCT01140906, NCT00596817​.

Integrity signals

Registry

Crossref · 10.4088/jcp.16m10744

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Existing TRD definitions fail to take into consideration the social, economic, anamnestic and interpersonal factors which, alone or in combinations, are known to moderate antidepressant response.

    “Further drawbacks of existing TRD defi­ nitions are that they fail to take into consid­ eration the social, economic, anamnestic (e.g., adverse childhood experiences) and interpersonal factors which, alone or in combinations, are known to moderate antidepressant response 1,44,47,71,75-­ 81 .”

    From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [76]

  • Vortioxetine has demonstrated benefits for sustained and selective attention as well as depressive symptoms in adults with MDD.

    “Vortioxetine, a relatively newer serotonin reuptake inhibitor (SRI) with mixed agonist/antagonist/partial-agonist effects, is a notable exception that has demonstrated benefits for sustained and selective attention as well as depressive symptoms in adults with MDD103,104.”

    From Paying attention to attention in depression (2019) · cites this paper as [104]

  • The lack of CBT effect could be due to employed people differing systemically from general or clinical populations in symptom profile, function and response.

    “This could be due to recent evidence that shows employed people differ systemically from the general or clinical in terms of symptom profile, function and response [26].”

    From Effectiveness of eHealth interventions for reducing mental health conditions in employees: A systematic review and meta-analysis (2017) · cites this paper as [26]

  • Employed people differ systemically from general or clinical populations used in most eHealth studies in terms of symptom profile, risks, function and response.

    “However, we know employed people differ systemically from both general or clinical populations used in most eHealth studies (in terms of symptom profile, risks, function and response [26])”

    From Effectiveness of eHealth interventions for reducing mental health conditions in employees: A systematic review and meta-analysis (2017) · cites this paper as [26]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
McIntyre, R. S., Florea, I., Tonnoir, B., Loft, H., Lam, R. W., & Christensen, M. C.
Affiliations
  • University Health Network (CA)
  • Lundbeck (Denmark) (DK)
  • University of British Columbia (CA)
Corresponding author
McIntyre, Roger S.
ORCID
Venue
The Journal of Clinical Psychiatry
Publisher
Physicians Postgraduate Press, Inc
Published
2016-10-25
Volume
78
Issue
01
Pages
115-121
ISSN
0160-6689 (ISSN-L)
DOI
10.4088/jcp.16m10744
OpenAlex
W2534049957
Semantic Scholar
8c39e94f14edfe382b59073700fbbd8cb376ef99
Cited by
100
References
24
Citations by year
2026: 4 · 2025: 10 · 2024: 10 · 2023: 9 · 2022: 10 · 2021: 18 · 2020: 7 · 2019: 10 · 2018: 9 · 2017: 12 · 2016: 1
FWCI
8.63
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
vortioxetine, major depressive disorder, cognitive function, working adults, occupational depression, Digit Symbol Substitution Test, Trail Making Test, Stroop task, duloxetine, depressive symptoms, FOCUS trial
MeSH terms
Vortioxetine, Adult, Depressive Disorder, Major, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Efficiency, Female, Humans, Male, Neuropsychological Tests, Piperazines, Psychometrics, Sulfides, Treatment Outcome, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review